Mendenhall TF Partners
Overview
Mendenhall TF Partners is a TheranosTheranosTheranos was a blood-testing company founded in 2003 by Elizabeth Holmes and based in Palo Alto, California, which offered retail testing with Walgreens and was valued at up to $9 billion before regulatory sanctions and criminal charges over alleged fraud in its technology and financial claims led to its dissolution in 2018.Open the full entry investment vehicle. John Howard Decker’s public FINRA disclosure describes it as a single-purpose LLC holding privately issued Theranos shares and records his participation as an investor.[1]
Contents5 sections
Key facts
2014Investment Record
2022Testimony at Balwani’s Trial
Pat Mendenhall testified at Balwani’s trial on April 29, 2022. The court subsequently explained that Holmes’s statements and promotional claims in a 2013 Wall Street JournalThe Wall Street JournalThe Wall Street Journal is a U.S. news publication founded in 1889, with a focus on business, finance and economics. It is published by Dow Jones, part of News Corp.Open the full entry article were significant to his investment decision.[3]
2023Restitution
On May 16, 2023, the court awarded Mendenhall TF Partners $1,312,500 in the final investor restitution schedule, jointly and severally payable by Holmes and Balwani. The order did not establish payment.[4]
Sources
- BrokerCheck Report — John Howard Decker, CRD 808126 (opens in a new window)
- United States v. Holmes — Order on Sentencing, Document 1712 (opens in a new window)
- United States v. Balwani — Order on Sentencing, Document 1730 (opens in a new window)
- Order on Restitution, United States v. Holmes and Balwani, No. 5:18-cr-00258-EJD, Document 1760 (opens in a new window)